Company Profile: Quris AI
Overview
Quris AI is a pioneering artificial intelligence innovator dedicated to transforming the pharmaceutical drug development landscape. The company utilizes its groundbreaking Bio-AI Clinical Prediction Platform to foresee which drug candidates are most likely to succeed in human trials, thus substantially decreasing costs related to failed clinical trials. Quris AI's platform synergizes machine learning, generative models, and cutting-edge patients-on-a-chip technology to formulate an advanced drug safety prediction system. Headquartered in both Boston and Tel Aviv, Quris AI is positioned at the epicenter of tech and pharma innovation.
Leadership and Key Personnel
Helmed by a team of renowned experts, Quris AI’s leadership includes:
- Isaac Bentwich, MD – Founder & CEO
- Yossi Haran – Co-Founder & CTO
- Orit Shaked, PhD – Chief Business Officer
- Chen Barshai – Chief Product and Partnerships Officer
- Yossi Ben Amram – President
- Noam Atar – CFO
The advisory board boasts industry luminaries such as Prof. Robert Langer, co-founder of Moderna, and Nobel Laureate Aaron Ciechanover, enhancing the company's potential to innovate and disrupt.
Strategic Developments
Quris AI recently achieved a pivotal integration with Merck KGaA, providing the pharma giant with their BioAI platform to assess small molecule drug safety, with a focus on mitigating liver toxicity risks. This partnership represents a crucial endorsement of Quris AI's technology. Moreover, Quris AI strategically acquired Nortis, a leader in organ-on-chip technology, enhancing their platform's capabilities with kidney-on-chip technology.
Financials and Funding
Quris AI has successfully garnered a total of $53.4 million in funding, with significant contributions from SoftBank Vision Fund 2, Vox Capital, and Tau Capital. Their seed funding round closed at $37 million, reflecting strong investor confidence in their AI-driven approach.
Collaborations and Impact
The extended cooperation with Merck KGaA and the acquisition of Nortis are testaments to Quris AI’s commitment to impactful partnerships, aimed at streamlining drug development processes and reducing failure rates in the industry by addressing a traditional 89% drug failure rate.
Mission and Values
Quris AI is devoted to fostering innovation rooted in Environmental, Social, and Governance (ESG) principles. The company champions diversity and inclusivity within its workforce and strives to create a positive societal impact through its transformative drug development technologies.
Competitor Profile and Market Positioning
Key Competitors
1. Exscientia
Exscientia stands out as a leading pharmatech firm employing AI and ML for drug discovery and design. The company's forte lies in precision medicine, facilitating expedited development of effective medicines through an end-to-end AI platform, integrating quantitative inputs from clinical trials.
2. Recursion Pharmaceuticals
As a clinical-stage biotech entity, Recursion Pharmaceuticals focuses on demystifying biology for drug discovery through automation, AI, and ML. Their leadership in the TechBio sphere is underlined by their substantial biological dataset and high-throughput labs that elucidate gene-compound relationships.
3. Insitro
Insitro redefines drug discovery via a data-driven and ML-infused approach. Specializing in metabolism, oncology, and neuroscience, Insitro's proprietary platform facilitates understanding and intervention in diseases, providing sharper therapeutic insights while cutting down development timeframes.
Strategic Advantages
Quris AI’s competitive edge within the industry is bolstered by:
- Innovative Platform: The unique 'Patients-on-a-Chip' technology allows for real-time nano-sensing, providing unparalleled predictions of human drug responses.
- AI-Driven Predictive Models: The BioAI Clinical Prediction Platform excels in accurate forecasts, effectively diminishing clinical trial risks and expenses.
- Global Recognition: As an acclaimed leader in healthcare technology, Quris AI continues to push significant advancements, cementing its role as a frontrunner in AI-driven pharma development.
Through a sustained focus on innovation and strategic partnerships, Quris AI is poised to maintain its upward trajectory and solidify its leadership position in AI-enhanced pharmaceutical development.
